Protalix BioTherapeutics (PLX) Cash from Operations (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Cash from Operations of 22025000.0 for Q1 2026, up 535.45% year-over-year from 3466054.26 in Q1 2025, and up 984.98% quarter-over-quarter from 2030000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Cash from Operations (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 22025000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 535.45% year-over-year to 22025000.0; the TTM figure through Mar 2026 stood at 15090000.0 (up 2738.11% YoY), while the FY2025 annual figure was 11993000.0, down 238.26% from the prior year.
- Cash from Operations for Q1 2026 stood at 22025000.0, up from 2030000.0 in the prior quarter.
- The five-year high for Cash from Operations was 22025000.0 in Q1 2026, with the low at 9204000.0 in Q3 2022.
- The 5-year median for Cash from Operations is 2998000.0 (2023), against an average of 447764.71.
- The sharpest annual moves came in 2022 and 2026: Cash from Operations tumbled 389.57% in 2022, then surged 535.45% in 2026.
- Protalix BioTherapeutics' Cash from Operations stood at 2611000.0 in 2022, then surged by 237.69% to 3595000.0 in 2023, then rose by 11.02% to 3991000.0 in 2024, then tumbled by 49.14% to 2030000.0 in 2025, then jumped by 984.98% to 22025000.0 in 2026.
- Business Quant data shows PLX's Cash from Operations at 22025000.0 in Q1 2026, 2030000.0 in Q4 2025, and 3732000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.40 Mn |
| Jun 30, 2026 | -10.40 Mn |
| Mar 31, 2026 | 22.03 Mn |
| Mar 31, 2026 | 22.03 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | -3.73 Mn |
| Sep 30, 2025 | -3.73 Mn |
| Jun 30, 2025 | -5.23 Mn |
| Jun 30, 2025 | -5.23 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Mar 31, 2024 | 4.19 Mn |
| Mar 31, 2024 | 4.19 Mn |